Form 4: Werewolf Therapeutics Executive Granted Stock Options

Ellen Lubman, Chief Business Officer of Werewolf Therapeutics, Inc., was granted stock options to purchase 131,900 shares of common stock on January 2, 2025.

Summary

• Ellen Lubman, the Chief Business Officer of Werewolf Therapeutics, Inc. (HOWL), was granted stock options on January 2, 2025.
• The options allow her to purchase 131,900 shares of Werewolf Therapeutics' common stock at an exercise price of $1.56 per share.
• The options vest in equal monthly installments over four years, starting one month after the Vesting Commencement Date of January 1, 2025, and continuing through January 1, 2029.
• The options expire on December 31, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it signals confidence in the executive and aligns their interests with shareholders.

Positives

• The granting of stock options to a key executive aligns her interests with those of the shareholders, incentivizing her to contribute to the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key talent, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies.
• The size of the grant is typical for a Chief Business Officer in a company of Werewolf Therapeutics' size and stage of development.
• Comparable companies such as Arcus Biosciences and Relay Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the option grant positively as it incentivizes the CBO to drive company growth.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates